Reinhart Partners Inc. boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 1.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,986 shares of the medical instruments supplier’s stock after buying an additional 21 shares during the period. Reinhart Partners Inc.’s holdings in Becton, Dickinson and were worth $387,000 as of its most recent filing with the SEC.
Other large investors have also recently made changes to their positions in the company. Cohen Lawrence B boosted its stake in shares of Becton, Dickinson and by 39.1% in the first quarter. Cohen Lawrence B now owns 4,272 shares of the medical instruments supplier’s stock worth $784,000 after buying an additional 1,200 shares during the period. Rockland Trust Co. purchased a new stake in shares of Becton, Dickinson and during the first quarter worth about $307,000. Wells Fargo & Company MN boosted its stake in shares of Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock worth $602,246,000 after buying an additional 39,362 shares during the period. Integrated Wealth Management boosted its stake in shares of Becton, Dickinson and by 3.4% in the first quarter. Integrated Wealth Management now owns 5,444 shares of the medical instruments supplier’s stock worth $999,000 after buying an additional 181 shares during the period. Finally, Quadrature Capital Ltd purchased a new stake in shares of Becton, Dickinson and during the fourth quarter worth about $944,000. Institutional investors and hedge funds own 75.42% of the company’s stock.
Becton, Dickinson and Company (NYSE:BDX) opened at 201.01 on Wednesday. The stock has a 50 day moving average of $194.41 and a 200 day moving average of $184.18. The company has a market cap of $42.88 billion, a price-to-earnings ratio of 33.38 and a beta of 1.05. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $201.44.
Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.23 by $0.07. Becton, Dickinson and had a return on equity of 25.37% and a net margin of 10.67%. The company had revenue of $2.97 billion during the quarter, compared to the consensus estimate of $2.92 billion. During the same quarter in the prior year, the firm posted $2.18 earnings per share. The firm’s revenue was down 3.2% compared to the same quarter last year. Equities research analysts predict that Becton, Dickinson and Company will post $9.45 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, June 30th. Investors of record on Friday, June 9th were issued a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.45%. The ex-dividend date of this dividend was Wednesday, June 7th. Becton, Dickinson and’s payout ratio is presently 48.26%.
WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/07/19/reinhart-partners-inc-has-387000-stake-in-becton-dickinson-and-company-bdx.html.
BDX has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $206.00 target price for the company in a research report on Tuesday, April 11th. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the stock from $210.00 to $180.00 in a report on Friday, June 30th. BidaskClub raised shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Jefferies Group LLC reissued a “buy” rating and set a $200.00 price objective on shares of Becton, Dickinson and in a report on Wednesday, March 29th. Finally, Evercore ISI raised shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $186.00 to $200.00 in a report on Monday, April 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $192.17.
In related news, VP Jeffrey S. Sherman sold 28,765 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total value of $5,349,714.70. Following the sale, the vice president now directly owns 70,821 shares in the company, valued at $13,171,289.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.40% of the company’s stock.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
